At the ECC 2015, James Yao reported early data from the RADIANT-4 placebo-controlled trial of everolimus in patients with advanced-stage nonfunctioning gastrointestinal or lung neuroendocrine tumour (NET). Median progression-free survival (PFS) was improved with everolimus (11.0 months versus 3.9 months; HR 0.48, P <0.00001), with a trend towards a significant improvement in overall survival (HR 0.64, P = 0.037). Everolimus is the first agent with demonstrated activity against lung NET in a randomized trial; data from the RADIANT trial series now support its use in patients with advanced-stage NET, independent of primary tumour origin. Discussant Enrique Grande questioned the relevance of the findings, citing the need for comparisons of everolimus against and/or in combination with somatostatin analogues, which have been associated with similar results.
References
Yao, J. et al. Everolimus in advanced non-functional neuroendocrine tumours (NET) of lung or gastrointestinal (GI) origin: efficacy and safety results from the placebo-controlled, double-blind, multicentre, phase 3 RADIANT-4 study [abstract LBA 5]. Presented at the ECC 2015
Rights and permissions
About this article
Cite this article
RADIANT-4 trial—NET improvement with everolimus?. Nat Rev Clin Oncol 12, 684 (2015). https://doi.org/10.1038/nrclinonc.2015.181
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2015.181
